RxDoctor Payments Data

Natalie Pierce, PA

Medical · Sherman, NYNPI 1093780025

Payments from drug & device makers

$837in general payments, 2019–2025

Across 39 payments — averaging $21.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$235
  • Biomarin Pharmaceutical Inc.$108
  • Lilly USA, LLC$102
  • AstraZeneca$64
  • Pfizer$56
  • Boston Scientific$49
  • plus $223 from 9 others

What the payments were for

  • Food & beverage$837100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$837 in reported general payments places this provider in the 65th percentile of 2,395 medical providers in New York.

See all medical providers in New York

Medicare billing

Part B allowed, 2024
$30,493
Medicare patients
97
Services billed
451

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban50$47,338
FarxigaDapagliflozin Propanediol30$37,957
JardianceEmpagliflozin33$37,592
TrulicityDulaglutide13$18,055
Breo ElliptaFluticasone/Vilanterol26$12,922
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$11,957
Repatha SureclickEvolocumab13$7,150
Lantus SolostarInsulin Glargine,hum.Rec.Anlog29$4,695
Fluticasone-SalmeterolFluticasone Propion/Salmeterol14$3,241
Arnuity ElliptaFluticasone Furoate18$3,157
Albuterol Sulfate HfaAlbuterol Sulfate72$2,097
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen92$2,007
Atorvastatin Calcium204$1,731
Levothyroxine Sodium125$1,723
Tolterodine Tartrate ErTolterodine Tartrate16$1,628

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$56$47,33850 claims
AstraZenecaFarxiga$64$37,95730 claims
GSKBreo Ellipta, Trelegy Ellipta, Arnuity Ellipta$20$28,03655 claims
Lilly USA, LLCTrulicity$102$18,05513 claims
AbbVieSynthroid$22$81013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 2,395 medical providers in New York.

Other medical in Sherman

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →